Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus METHYLTESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus METHYLTESTOSTERONE.
DANOCRINE vs METHYLTESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Category C
Category D/X
Androgen/Antigonadotropin
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."